AstraZeneca: Camizestrant Combo Significantly Delays Progression in Advanced Breast Cancer Trial
June 03, 2026
June 03, 2026
WILMINGTON, Delaware, June 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 trial
Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care
* * *
Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 trial
Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care